Analysis of hepatitis B surface antibody titers in B cell lymphoma patients after rituximab therapy

Annals of Hematology

Volumn 91, Issue 7, 2012, Pages 1007-1012

  Pei, Sung Nan ^a   Ma, Ming Chun ^a   Wang, Ming Chung ^a   Kuo, Ching Yuan ^a   Rau, Kun Min ^a   Su, Cheng Yu ^a   Chen, Chien Hung ^a  

^a CHANG GUNG UNIVERSITY   (Taiwan)

Author keywords

Hepatitis B surface antibody; Hepatitis B virus; Non Hodgkin's lymphoma; Rituximab

Indexed keywords

CYCLOPHOSPHAMIDE; DOXORUBICIN; FLUDARABINE; HEPATITIS B SURFACE ANTIBODY; IMMUNOGLOBULIN G; PREDNISOLONE; RITUXIMAB; VINCRISTINE;

ADULT; ADVANCED CANCER; AGED; ANTIBODY BLOOD LEVEL; ANTIBODY TITER; ARTICLE; B CELL LYMPHOMA; CANCER COMBINATION CHEMOTHERAPY; CANCER STAGING; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; HEPATITIS B; HUMAN; IMMUNOGLOBULIN BLOOD LEVEL; MALE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROGNOSIS; SEROCONVERSION; VIRUS REACTIVATION;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CYCLOPHOSPHAMIDE; DOXORUBICIN; FEMALE; HEPATITIS B ANTIBODIES; HEPATITIS B SURFACE ANTIGENS; HUMANS; LYMPHOMA, B-CELL; MALE; MIDDLE AGED; PREDNISONE; RETROSPECTIVE STUDIES; SEROLOGIC TESTS; TITRIMETRY; VIDARABINE; VINCRISTINE; VIRUS ACTIVATION;

EID: 84862771957     PISSN: 09395555     EISSN: 14320584     Source Type: Journal    
DOI: 10.1007/s00277-012-1405-6     Document Type: Article

References (25)

1. K Matsue SI Kimura Y Takanashi KI Iwama H Fujiwara M Yamakura M Takeuchi 2010 Reactivation of hepatitis B virus after rituximab-containing treatment in patients with CD20-positive B-cell lymphoma Cancer 116 20 4769 4776 10.1002/cncr.25253 20597091 10.1002/cncr.25253
2. N Niitsu Y Hagiwara K Tanae M Kohri N Takahashi 2010 Prospective analysis of hepatitis B virus reactivation in patients with diffuse large B-cell lymphoma after rituximab combination chemotherapy J Clin Oncol 28 34 5097 5100 10.1200/JCO.2010.29.7531 20837949 10.1200/JCO.2010.29.7531 1:CAS:528: DC%2BC3MXltlKnsg%3D%3D
3. SN Pei CH Chen CM Lee MC Wang MC Ma TH Hu CY Kuo 2010 Reactivation of hepatitis B virus following rituximab-based regimens: a serious complication in both HBsAg-positive and HBsAg-negative patients Ann Hematol 89 3 255 261 10.1007/s00277-009-0806-7 19697028 10.1007/s00277-009-0806-7 1:CAS:528:DC%2BC3cXpsVSiug%3D%3D
4. W Yeo TC Chan NW Leung WY Lam FK Mo MT Chu HL Chan EP Hui KI Lei TS Mok PK Chan 2009 Hepatitis B virus reactivation in lymphoma patients with prior resolved hepatitis B undergoing anticancer therapy with or without rituximab J Clin Oncol 27 4 605 611 10.1200/JCO.2008.18.0182 19075267 10.1200/JCO.2008.18. 0182 1:CAS:528:DC%2BD1MXivFyju7s%3D
5. CW Wang LC Wang MH Chang YH Ni HL Chen HY Hsu DS Chen 2005 Long-term follow-up of hepatitis B surface antibody levels in subjects receiving universal hepatitis B vaccination in infancy in an area of hyperendemicity: correlation between radioimmunoassay and enzyme immunoassay Clin Diagn Lab Immunol 12 12 1442 1447 10.1128/CDLI.12.12.1442-1447.2005 16339069 1:CAS:528: DC%2BD2MXhtlert7%2FL
6. TA Lister D Crowther SB Sutcliffe E Glatstein GP Canellos RC Young SA Rosenberg CA Coltman M Tubiana 1989 Report of a committee convened to discuss the evaluation and staging of patients with Hodgkin's disease: Cotswolds meeting J Clin Oncol 7 11 1630 1636 2809679 1:STN:280:DyaK3c%2FjvFCnsA%3D%3D
7. A predictive model for aggressive non-Hodgkin's lymphoma. The International Non-Hodgkin's Lymphoma Prognostic Factors Project (1993). N Engl J Med 329 (14):987-994. doi:10.1056/NEJM199309303291402
8. JM Vose BK Link ML Grossbard M Czuczman A Grillo-Lopez P Gilman A Lowe LA Kunkel RI Fisher 2001 Phase II study of rituximab in combination with chop chemotherapy in patients with previously untreated, aggressive non-Hodgkin's lymphoma J Clin Oncol 19 2 389 397 11208830 1:CAS:528:DC%2BD3MXhtVekt7o%3D
9. J Moore D Ma R Will P Cannell M Handel S Milliken 2004 A phase II study of Rituximab in rheumatoid arthritis patients with recurrent disease following haematopoietic stem cell transplantation Bone Marrow Transplant 34 3 241 247 10.1038/sj.bmt.1704570 15235579 10.1038/sj.bmt.1704570 1:CAS:528: DC%2BD2cXlslGnsrY%3D
10. MS Czuczman AJ Grillo-Lopez CA White M Saleh L Gordon AF LoBuglio C Jonas D Klippenstein B Dallaire C Varns 1999 Treatment of patients with low-grade B-cell lymphoma with the combination of chimeric anti-CD20 monoclonal antibody and CHOP chemotherapy J Clin Oncol 17 1 268 276 10458242 1:CAS:528: DyaK1MXltVyrsA%3D%3D
11. P McLaughlin AJ Grillo-Lopez BK Link R Levy MS Czuczman ME Williams MR Heyman I Bence-Bruckler CA White F Cabanillas V Jain AD Ho J Lister K Wey D Shen BK Dallaire 1998 Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program J Clin Oncol 16 8 2825 2833 9704735 1:CAS:528:DyaK1cXlsFCgu7c%3D
12. LD Piro CA White AJ Grillo-Lopez N Janakiraman A Saven TM Beck C Varns S Shuey M Czuczman JW Lynch JE Kolitz V Jain 1999 Extended Rituximab (anti-CD20 monoclonal antibody) therapy for relapsed or refractory low-grade or follicular non-Hodgkin's lymphoma Ann Oncol 10 6 655 661 10442187 10.1023/A:1008389119525 1:STN:280:DyaK1MzntVOktw%3D%3D
13. DG Maloney AJ Grillo-Lopez CA White D Bodkin RJ Schilder JA Neidhart N Janakiraman KA Foon TM Liles BK Dallaire K Wey I Royston T Davis R Levy 1997 IDEC-C2B8 (Rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma Blood 90 6 2188 2195 9310469 1:CAS:528:DyaK2sXmtVOqsL0%3D
14. G Salles JF Seymour F Offner A Lopez-Guillermo D Belada L Xerri P Feugier R Bouabdallah JV Catalano P Brice D Caballero C Haioun LM Pedersen A Delmer D Simpson S Leppa P Soubeyran A Hagenbeek O Casasnovas T Intragumtornchai C Ferme MG da Silva C Sebban A Lister JA Estell G Milone A Sonet M Mendila B Coiffier H Tilly 2011 Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial Lancet 377 9759 42 51 10.1016/S0140-6736(10) 62175-7 21176949 10.1016/S0140-6736(10)62175-7 1:CAS:528:DC%2BC3MXms1Wq
15. LE van der Kolk JW Baars MH Prins MH van Oers 2002 Rituximab treatment results in impaired secondary humoral immune responsiveness Blood 100 6 2257 2259 12200395
16. B Coiffier C Haioun N Ketterer A Engert H Tilly D Ma P Johnson A Lister M Feuring-Buske JA Radford R Capdeville V Diehl F Reyes 1998 Rituximab (anti-CD20 monoclonal antibody) for the treatment of patients with relapsing or refractory aggressive lymphoma: a multicenter phase II study Blood 92 6 1927 1932 9731049 1:CAS:528:DyaK1cXmtVOhtbs%3D
17. R Liang 2009 How I treat and monitor viral hepatitis B infection in patients receiving intensive immunosuppressive therapies or undergoing hematopoietic stem cell transplantation Blood 113 14 3147 3153 10.1182/blood-2008-10-163493 19144986 10.1182/blood-2008-10-163493 1:CAS:528:DC%2BD1MXksFWqsLw%3D
18. HJ Ng LC Lim 2001 Fulminant hepatitis B virus reactivation with concomitant listeriosis after fludarabine and rituximab therapy: case report Ann Hematol 80 9 549 552 11669307 10.1007/s002770100346 1:STN:280: DC%2BD3Mrms1CitA%3D%3D
19. M Yagci GT Sucak R Haznedar 2000 Fludarabine and risk of hepatitis B virus reactivation in chronic lymphocytic leukemia Am J Hematol 64 3 233 234 10861827 10.1002/1096-8652(200007)64:3<233::AID-AJH21>3.0.CO;2-W 1:STN:280:DC%2BD3czitVCmsw%3D%3D
20. M Watanabe A Shibuya Y Tsunoda M Danbara R Ishii M Ohsaka J Takada Y Tanaka Y Okuwaki T Minamino H Hidaka T Nakazawa R Horie M Higashihara W Koizumi 2011 Re-appearance of hepatitis B virus following therapy with rituximab for lymphoma is not rare in Japanese patients with past hepatitis B virus infection Liver Int 31 3 340 347 10.1111/j.1478-3231.2010.02417.x 21134110 10.1111/j.1478-3231.2010.02417.x
21. M Miyagawa M Minami K Fujii R Sendo K Mori D Shimizu T Nakajima K Yasui Y Itoh M Taniwaki T Okanoue T Yoshikawa 2008 Molecular characterization of a variant virus that caused de novo hepatitis B without elevation of hepatitis B surface antigen after chemotherapy with rituximab J Med Virol 80 12 2069 2078 10.1002/jmv.21311 19040281 10.1002/jmv.21311 1:CAS:528:DC%2BD1cXhsVemsbvN
22. National Comprehensive Cancer Network (2011) NCCN Clinical Practice Guidelines in Oncology: Non-Hodgkin's Lymphomas version 4.2011. Available at http://www.nccn.org/professionals/physician-gls/pdf/nhl.pdf. Accessed 2 Nov 2011.
23. European Association For The Study Of The L 2009 EASL Clinical Practice Guidelines: management of chronic hepatitis B J Hepatol 50 2 227 242 10.1016/j.jhep.2008.10.001 10.1016/j.jhep.2008.10.001
24. AS Lok BJ McMahon 2007 Chronic hepatitis B Hepatology 45 2 507 539 10.1002/hep.21513 17256718 10.1002/hep.21513 1:CAS:528:DC%2BD2sXisVKns7o%3D
25. M Cornberg U Protzer MM Dollinger J Petersen H Wedemeyer T Berg W Jilg A Erhardt S Wirth P Schirmacher WE Fleig MP Manns 2007 Prophylaxis, diagnosis and therapy of hepatitis B virus (HBV) infection: the German guidelines for the management of HBV infection Z Gastroenterol 45 12 1281 1328 10.1055/s-2007- 963714 18080231 10.1055/s-2007-963714 1:CAS:528:DC%2BD1cXjt12ks7k%3D